← All trials
NCT05773001
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 18, 2023
- Primary completion
- May 31, 2028
- Completion date
- May 31, 2028
- First posted
- Mar 17, 2023
- Last posted
- Jul 3, 2023
- Enrollment
- 100
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Duke UniversityLead sponsor
- National Institutes of Health (NIH)Collaborator
- National Institute of Environmental Health Sciences (NIEHS)Collaborator
- Duke UniversityOverall official - principal investigator
- Duke UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.